About 17 results found for searched term "C16" (0.051 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2057 | Dexrazoxane hydrochloride | Topoisomerase |
| Cardioxane, ICRF-187, NSC169780, Zinecard，DXZ | ||
| Dexrazoxane HCl (ICRF-187, ADR-529, DXZ) is an iron chelator that can be used to prevent DOX-induced cardiotoxicity. | ||
| M3986 | Bruceantin | Antibiotic |
| (-)-Bruceantin; NCI165563; NSC165563 | ||
| Bruceantin was first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer. | ||
| M4450 | Acteoside | PKC |
| Verbascoside; Kusaginin; TJC160 | ||
| Acteoside is isolated from Acanthus mollis, acts as an ATP-competitive inhibitor of PKC, with an IC50 of 25 µM, and has antitumor, anti-inflammatory and antineuropathic pain activity. | ||
| M6553 | C16 | Apoptosis |
| PKR-IN-C16 | ||
| C16 is a pKR inhibitor. | ||
| M6804 | IBMX | PDE |
| IMX; Isobutylmethylxanthine; Methylisobutylxanthine; NSC165960; SC2964; 3-isobutyl-1-methylxanthine | ||
| IBMX is a pDE inhibitor (non-selective) with IC50 values of 6.5±1.2, 26.3±3.9 and 31.7±5.3 μM for PDE3, 4 and 5 respectively. | ||
| M7100 | PAF (C16) | Others |
| C16-PAF | ||
| PAF (C16) is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability. | ||
| M7746 | Dexrazoxane | Others |
| ICRF187; NSC169780；DXZ | ||
| Dexrazoxane (ICRF-187, ADR-529, DXZ) is an iron chelator that can be used to prevent DOX-induced cardiotoxicity. | ||
| M10332 | Vapreotide acetate | Neurokinin Receptor |
| BMY-41606; RC160; Octastatin acetate | ||
| Vapreotide acetate (BMY-41606 acetate; RC160 acetate) is a neurokinin-1 (NK1) receptor antagonist with IC50 value of 330 nM. | ||
| M11324 | BC1618 | AMPK |
| BC1618, an orally active Fbxo48 inhibitor, stimulates Ampk signaling (preventing activated pAmpkα from being degraded by fBXO48-mediated proteasome). BC1618 promotes mitochondrial division, autophagy and insulin sensitivity in the liver. | ||
| M27671 | Vapreotide | Neurokinin Receptor |
| RC160; BMY 41606 | ||
| Vapreotide is a neurokinin-1 (NK1) receptor antagonist, with an IC50 of 330 nM. | ||
| M28124 | TRC160334 | HIF |
| TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury. | ||
| M29665 | C16-Ceramide | p53 |
| C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding. | ||
| M30481 | NSC16168 | Others |
| NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer. | ||
| M30988 | Alkynyl Palmitic Acid | PROTAC Linker |
| Alk-C16 | ||
| Alkynyl Palmitic Acid (Alk-C16) is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. | ||
| M55679 | Recombinant Human CA125 Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| FLJ14303; MUC16; mucin 16 | ||
| CA125 is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. CA125 binds galectin-1 on immune cells and enhances its expression on tumor cells. CA125-expressing tumors adhere to NK cells, down-regulate CD16 and suppress NK response, which may promote immune evasion. | ||
| M56298 | SNC162 | Opioid Receptor |
| SNC162 is a delta-opioid receptor agonist with an IC50 of 0.94 nM. | ||
| M58607 | OPC-163493 | Mitochondrial Related |
| OPC163493 | ||
| OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
